Break the monopoly of foreign technology domestic full magnetic levitation artificial heart has been approved for marketing

Recently, at the 2nd Critical Care Heart Disease Conference held in Shenzhen, there came a good news for heart failure patients. With the recent approval of Suzhou Concentric Medical's innovative product "implantable left ventricular assist system CH-VAD" (artificial heart), marking China's first full magnetic levitation artificial heart with complete independent intellectual property rights has officially started the process of commercialization, China's surgical treatment of heart failure has entered the era of artificial heart.

Artificial heart

The heart mainly provides mechanical support for the blood circulation of patients with progressive refractory left heart failure, and is mostly used for transitional treatment before heart transplantation or restoration of heart function. Heart failure is a terminal stage of heart disease, known as the "cancer" of heart disease, and treatment for this type of disease has a series of unfavorable factors, such as high cost, recurring disease, and low survival rate. At the same time, because these diseases need to be treated by heart transplantation, and the number of heart transplants in China is still at a very low level due to the difficulty of obtaining suitable donors, so the artificial heart has become the biggest "savior" for these patients. The launch of the national artificial heart, breaking the monopoly of foreign countries on this technology, for heart failure patients, is a good news.

Dr. Chen Chen, founder of Concentricity Healthcare

It is reported that Concentricity Healthcare's "implantable left ventricular assist system CH-VAD" is the first domestic artificial heart approved by the NMPA with complete independent intellectual property rights in China, and is also the first fully magnetic levitation artificial heart approved by the NMPA in the world, and is the first fully magnetic levitation artificial heart approved by the NMPA. It is also the first NMPA-approved full magnetic levitation artificial heart in the world, marking the commercialization of the new generation of global technology route (full magnetic levitation technology route) ventricular assist device products in China, which will open a new era of heart failure treatment in China.